Ansell: the Dunlop offshoot that quietly gloves the world

Walk into an operating theatre in Frankfurt, a food-processing plant in Ohio or a mine site in the Pilbara, and there is a fair chance the gloves on someone's hands trace back to a rubber factory that once made tyres in suburban Melbourne. Ansell doesn't put its name on much that ordinary people see. No flagship stores, no ad campaigns during the footy, no logo on a jersey. It just makes the thing between your skin and whatever might hurt you, and it turns out that is an enormous business if you do it in enough countries for long enough.

I've been circling back to Ansell for a few months now, partly because it keeps showing up in conversations about protective equipment supply chains, and partly because it's the kind of company that fits neatly into what this section is about: firms Australians barely notice that quietly dominate a global niche. Ansell is protective gloves and barrier products, essentially, and it has been at it for roughly a century, in one corporate form or another.

The Dunlop roots of a global glove business

Ansell's origins sit inside the old Dunlop Rubber empire, the same Australian rubber and tyre business that once had its hands in everything from bicycle tyres to golf balls. Latex examination and household gloves were a Dunlop sideline for decades before they became the point. The name Ansell itself comes from Eric Ansell, who started producing rubber goods, including condoms and household gloves, in Melbourne in the 1890s and 1900s, and whose operation was later absorbed into the Dunlop group.

What eventually became the standalone company we know today emerged through a long process of corporate reshuffling as Dunlop's industrial and rubber interests were carved up, sold off and refocused across the twentieth century. By the time the modern Ansell name was applied to the protective products business in the 1990s, it had already shed the tyre-making and general rubber-goods identity and become something narrower and, frankly, more useful: a company obsessed with what happens at the interface between a human hand and a hazard.

That history matters because it explains something about the culture. Ansell isn't a startup that stumbled into gloves. It's an old industrial concern that kept narrowing its focus until it found a niche worth owning outright, then spent decades defending and expanding it.

What "protective gloves" actually covers

It's tempting to hear "gloves" and picture a fairly boring, low-margin commodity. That undersells what Ansell actually does. The business splits broadly into two arms: industrial protection, covering things like chemical-resistant gloves for factory workers, cut-resistant gloves for meat processing and construction, and clothing for hazardous environments; and healthcare, covering surgical and examination gloves along with other single-use barrier products used across hospitals and clinics.

Each of those categories has its own standards regime, which is a large part of why the business is harder to disrupt than it looks. Industrial gloves are rated against cut-resistance and chemical-permeation standards under frameworks like the relevant ISO and ANSI/ISEA classifications used across different markets; healthcare products sit under medical device regulation in each jurisdiction they're sold into, from the US FDA framework to Europe's medical device regulation. Getting a glove approved isn't like getting a t-shirt onto a shelf. It's closer to getting a piece of safety equipment certified, because that is exactly what it is.

That regulatory density is, I'd argue, underappreciated as a moat. Anyone can sew a glove. Not everyone can get it approved for surgical use in a dozen countries and keep that approval through however many audit cycles. Ansell's scale means it can spread that compliance cost over enormous volumes; a smaller regional player is stuck absorbing the same fixed cost over a fraction of the units.

The 2020 stress test nobody wanted

The pandemic did for Ansell's public profile what decades of steady industrial supply contracts never quite managed. Suddenly the entire planet cared, urgently, about where examination gloves and protective barriers came from, and Ansell was one of the handful of companies with the manufacturing footprint to actually respond at scale. Demand for medical and protective gloves spiked hard through 2020 and into 2021, and Ansell's results reflected it, with the company reporting sharply higher earnings on the back of surging orders before that demand inevitably normalised as the acute phase of the crisis passed and customers worked through the stockpiles they'd built.

What I find more interesting than the spike itself is what it revealed about the supply chain underneath. A huge share of global rubber glove manufacturing capacity sits in Malaysia and Thailand, produced by a small number of very large contract manufacturers, and companies like Ansell sit partly as vertically integrated producers and partly as buyers and distributors layered on top of that regional manufacturing base. When the world suddenly needed billions more gloves than usual, the constraint wasn't demand, it was raw latex and factory throughput in a fairly concentrated part of Southeast Asia. Ansell's advantage was having relationships, contracts and its own capacity already locked in when everyone else was scrambling.

Reading the numbers, not just the story

This is the bit where, as a matter of habit, I want to look past the good yarn and check what the business actually earns. Ansell has been listed on the ASX for a long time and reports in US dollars, reflecting where the bulk of its revenue and costs sit — a reminder that despite the Australian listing and Melbourne heritage, this is a genuinely global operation with limited exposure to the Australian dollar cycle that trips up a lot of purely domestic industrials.

The post-pandemic normalisation was real and it wasn't gentle. Glove prices that had spiked during the shortage came back down as manufacturing capacity across the industry caught up and then overshot, and Ansell, like its competitors, had to work through a period of margin pressure and destocking as customers ran down the excess inventory they'd built during the panic-buying years. That's a useful corrective for anyone tempted to treat 2020-21 as the new normal rather than the anomaly it was. The underlying business, in ordinary years, is a steadier, more modest-growth industrial and healthcare supplier, not a pandemic winner in perpetuity.

What I'd want to see in any given result, and what the company's own reporting to the ASX tends to emphasise, is the split between industrial and healthcare segment performance, because they don't move in lockstep. Industrial demand tracks manufacturing and construction activity in its major markets; healthcare demand is stickier, tied to hospital procurement cycles and, in normal years, grows more predictably with ageing populations and rising procedure volumes in markets like the US and Europe.

Why this counts as an invisible giant

I keep coming back to a simple test for whether a company belongs in this category: does it matter enormously to people who have never heard of it? Ansell passes easily. Surgeons who've never given the brand a thought are trusting its examination gloves during procedures. Workers in abattoirs and chemical plants across multiple continents are wearing cut-resistant or chemical-rated gloves that came off an Ansell production line, or one of the contract lines it manages, without a second glance at the label.

That's the pattern this section keeps returning to, and it's worth reading alongside Brambles and CHEP's blue pallet empire, another Australian-rooted business that became indispensable by owning the boring, essential infrastructure everyone else takes for granted. Ansell and Brambles don't compete for headlines the way a mining major or a bank does, but both built genuinely global positions in categories most people never think about until they're standing right in front of them. There's also a useful comparison with Computershare's dominance of global share registries, another case of an Australian company finding a structurally unglamorous niche and simply refusing to lose it to competitors over decades.

None of this means Ansell is a flawless business or a guaranteed compounder. Commodity glove pricing is genuinely cyclical, competition out of Asian manufacturers is real and persistent, and the healthcare segment carries its own regulatory and litigation risks that come with being a medical device supplier in multiple jurisdictions. But as an example of an Australian company that took a fairly unglamorous manufacturing niche, refused to be embarrassed by it, and built a genuinely global, still largely anonymous business on top of it, Ansell is about as clean a case study as this beat produces.

Next time you're at a service station or a hardware store and you pick up a box of disposable gloves off the shelf, have a look at the brand. It's a reasonable bet you'll recognise the name, even if you've never once thought about where it came from.